Documents tagged "Drug Administration"
Found 5 documents with this tag
DOJ-OGR-00005938.jpg
The image displays a scanned document with text written in English. The style of the document appears to be an official report or announcement from the FDA (Food and Drug Administration). There is visible information about a drug or treatment, including references to clinical trials and approval status. Due to the resolution and angle at which the photo was taken, some of the text may not be fully legible, but it's clear that the document pertains to healthcare regulations in the United States.
DOJ-OGR-00021241.jpg
The image shows a section of a printed document with visible text on it. The document appears to be an official report or announcement from the "Food and Drug Administration," as indicated by the text at the top. Below this header, there is a paragraph discussing certain aspects of the FDA's work, mentioning topics such as compliance inspections, enforcement actions, and collaborations. The background of the paper is white, and the text is primarily in black ink, which indicates that it might be from an office or official government document. There are no people or locations depicted in this image, and the focus is solely on the textual content.
HOUSE_OVERSIGHT_026601.txt
The document is a message to Global Conference attendees, outlining the program for the event which includes sessions on major economic and policy issues, new additions such as three late-afternoon plenary sessions featuring notable speakers like Eric Cantor and Al Gore, as well as updates on the final day's events including a closing session on investing in African prosperity with Rwandan President Paul Kagame, former British Prime Minister Tony Blair, philanthropist Bill Gates, and Rhonda Zygocki of Chevron. The conference takes place in Beverly Hills.
HOUSE_OVERSIGHT_026362.txt
The FDA has approved Praluent, a new cholesterol-lowering medicine for people with established heart disease whose risk is not adequately controlled by existing statin drugs. It is administered through an injection and its long-term effects are unknown. The approval of this drug marks a significant advancement in the battle against heart disease, particularly for patients who have been difficult to treat due to high levels of LDL cholesterol. However, the new drug's cost may pose financial challenges down the line.
HOUSE_OVERSIGHT_025888.txt
This document discusses the FDA approval of a new cholesterol-lowering drug called Praluent, which is manufactured by Regeneron Pharmaceuticals. The article highlights the potential benefits and costs associated with this medication, as well as its impact on the battle against heart disease. Notable individuals mentioned in the document include Sultan Bin Sulayem, Jeffrey Epstein, Forbes Staff writer Matthew Herper, and Steven Nissen of the Cleveland Clinic.